Dataset Information

Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

ABSTRACT: Imlifidase is a cysteine proteinase which specifically cleaves IgG, inhibiting Fc-mediated effector function within hours of administration. Imlifidase converts a positive crossmatch to a potential donor (T cell, B cell, or both), to negative, enabling transplantation to occur between previously HLA incompatible donor-recipient pairs. To date, 39 crossmatch positive patients received imlifidase prior to a kidney transplant in four single-arm, open-label, phase 2 studies. At 3 years, for patients who were AMR+ compared to AMR-, death-censored allograft survival was 93% vs 77%, patient survival was 85% vs 94%, and mean eGFR was 49 ml/min/1.73 m² vs 61 ml/min/1.73 m² , respectively. The incidence of AMR was 38% with most episodes occurring within the first month post-transplantation. Sub-analysis of patients deemed highly sensitized with cPRA ≥ 99.9%, and unlikely to be transplanted who received crossmatch-positive, deceased donor transplants had similar rates of patient survival, graft survival, and eGFR but a higher rate of AMR. These data demonstrate that outcomes and safety up to 3 years in recipients of imlifidase-enabled allografts is comparable to outcomes in other highly sensitized patients undergoing HLA-incompatible transplantation. Thus, imlifidase is a potent option to facilitate transplantation among patients who have a significant immunologic barrier to successful kidney transplantation. Clinical Trial: ClinicalTrials.gov (NCT02790437), EudraCT Number: 2016-002064-13.

SUBMITTER: Kjellman C

PROVIDER: S-EPMC9290474 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

Kjellman Christian C Maldonado Angela Q AQ Sjöholm Kristoffer K Lonze Bonnie E BE Montgomery Robert A RA Runström Anna A Lorant Tomas T Desai Niraj M NM Legendre Christophe C Lundgren Torbjörn T von Zur Mühlen Bengt B Vo Ashley A AA Olsson Håkan H Jordan Stanley C SC

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20210719 12

Imlifidase is a cysteine proteinase which specifically cleaves IgG, inhibiting Fc-mediated effector function within hours of administration. Imlifidase converts a positive crossmatch to a potential donor (T cell, B cell, or both), to negative, enabling transplantation to occur between previously HLA incompatible donor-recipient pairs. To date, 39 crossmatch positive patients received imlifidase prior to a kidney transplant in four single-arm, open-label, phase 2 studies. At 3 years, for patients ...[more]

PMID: 34236770

Similar Datasets

Project description:ImportanceRed blood cell transfusion (RBCT) is frequently required in the early post-kidney transplant period, but long-term outcomes associated with RBCT is controversial. Therefore, it may be relevant to investigate the association between RBCT characteristics and transplant outcomes.ObjectiveTo study the association between RBC storage duration and transplant outcomes.Design, setting, and participantsThis was a nationwide retrospective cohort study based on data linking between 2 prospective French nationwide registries. Clinical transplant parameters, outcomes, and RBCT characteristics were extracted from the CRISTAL registry of the Agence de la Biomédecine and the national database of the Etablissement Français du Sang. All 12 559 patients having received a first kidney transplant in France between January 1, 2002, and December 31, 2008, were included. Patients were followed up from transplant to graft loss, death with a functional graft, or data retrieval in June 2016. Data were analyzed from April 2019 to June 2022.ExposuresClinical outcomes of transplant recipients who underwent early RBCT were analyzed considering transfusion characteristics.Main outcomes and measuresCox proportional hazards regression models were fitted to evaluate transplant failure defined as graft loss or death with a functional graft.ResultsAmong 12 559 patients who underwent kidney transplant, 3483 received an RBCT during the first 14 days posttransplant. The median (IQR) age of patients was 53.0 (41.5-61.2) years, and 1929 patients (55.4%) were male. Median (IQR) follow-up was 7.8 (7.6-8.0) years. In multivariable analysis, longer (vs shorter) storage duration of transfused RBC was associated with a decrease in risk of transplant failure (hazard ratio, 0.99; 95% CI, 0.98-1.00 for each additional storage day; P = .06). Patients transfused with at least 1 RBC unit stored for more than 20 days had a 5% absolute decrease in transplant failure at 3 years and 7% at 5 years compared with those who received RBC stored for less than 20 days.Conclusions and relevanceIn this study, longer RBC storage duration was associated with a decreased risk of transplant failure among patients who received kidney transplants and RBC transfusions. Preferential use of RBC with longer storage duration might improve kidney graft survival following transplant and transfusion.

Dataset Information

Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

Publications

Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets